Research programme: Nanobodies - Ablynx/Kyowa Hakko Kirin

Drug Profile

Research programme: Nanobodies - Ablynx/Kyowa Hakko Kirin

Latest Information Update: 23 Sep 2009

Price : $50

At a glance

  • Originator Ablynx; Kirin Brewery
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 23 Sep 2009 This programme is still in active development
  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
  • 01 Jul 2007 Kirin Brewery is now called Kirin Holdings Company; it also launched Kirin Pharma as an independent pharmaceuticals business unit
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top